CAMBRIDGE, Mass. — U.S. regulators are delaying their determination on Moderna‘s COVID-19 vaccine for 12- to 17-year-olds whereas they examine the uncommon danger of coronary heart irritation, the corporate mentioned Sunday.
The corporate additionally mentioned it’ll delay submitting a request for emergency-use authorization of a decrease dose of the vaccine for 6- to 11-year-olds.
Coronary heart irritation is an exceedingly uncommon danger of each the Pfizer and Moderna vaccines, and it extra generally seen in younger males or boys. It’s tough for scientific trials to detect such a uncommon downside. And public well being officers have repeatedly careworn that COVID-19 itself may cause coronary heart irritation at increased charges than the uncommon instances attributable to the vaccine.
Within the U.S., the Moderna vaccine is allowed for folks 18 and older.
Moderna mentioned greater than 1.5 million adolescents around the globe have acquired its vaccine and that the variety of coronary heart irritation stories “doesn’t counsel an elevated danger” for these beneath 18.
The FDA final week moved to permit use of the Pfizer pictures in kids between 5 and 11. The Facilities for Illness Management and Prevention is debating that this week.
Moderna additionally has been testing two pictures, one month aside, for kids 6 to 11, at half the dose given to adults.
Copyright © 2021 The Washington Instances, LLC.
https://www.washingtontimes.com/news/2021/oct/31/fda-delays-decision-moderna-vaccine-adolescents/?utm_source=RSS_Feed&utm_medium=RSS | FDA delays determination on Moderna vaccine for adolescents